Cargando…

The role of BRCA1-IRIS in ovarian cancer formation, drug resistance and progression

Detalles Bibliográficos
Autor principal:	ElShamy, Wael M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965255/ https://www.ncbi.nlm.nih.gov/pubmed/27489859 http://dx.doi.org/10.18632/oncoscience.308

Ejemplares similares

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
por: Blanchard, Zannel, et al.
Publicado: (2015)

BRCA1-IRIS Overexpression Promotes Formation of Aggressive Breast Cancers
por: Shimizu, Yoshiko, et al.
Publicado: (2012)

BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells
por: Shimizu, Yoshiko, et al.
Publicado: (2012)

The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells
por: Ryan, Daniel, et al.
Publicado: (2019)

The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion
por: Bogan, Danielle, et al.
Publicado: (2017)

A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment
por: Ryan, Daniel, et al.
Publicado: (2017)

Correction: A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment
por: Ryan, Daniel, et al.
Publicado: (2017)

BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions
por: Sinha, Abhilasha, et al.
Publicado: (2016)

Aggressiveness Niche: Can It Be the Foster Ground for Cancer Metastasis Precursors?
por: ElShamy, Wael M., et al.
Publicado: (2016)

Targeting AXL and RAGE to prevent geminin overexpression-induced triple-negative breast cancer metastasis
por: Ryan, Daniel, et al.
Publicado: (2019)

Cost-effective BRCA Testing in Advanced Ovarian Cancer
por: Kim, Myungshin
Publicado: (2023)

A model of the BRCA1/BRCA2 network
por: Pujana, MA, et al.
Publicado: (2005)

Comments on: Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer
por: Kwon, Janice S.
Publicado: (2021)

BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
por: Li, Andrew G., et al.
Publicado: (2018)

Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells
por: Gardner, Lauren, et al.
Publicado: (2011)

Autophagy: New Insights into Its Roles in Cancer Progression and Drug Resistance
por: Nawrocki, Steffan T., et al.
Publicado: (2020)

The Physiology of the Iris
Publicado: (1858)

Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status?
por: Liu, Guo-Yan, et al.
Publicado: (2012)

American Academy of Ophthalmology Intelligent Research in Sight (IRIS®) Registry and the IRIS Registry Analytic Center Consortium
por: Lee, Cecilia S., et al.
Publicado: (2022)

Ovarian cancer: epigenetics, drug resistance, and progression
por: Xie, Weiwei, et al.
Publicado: (2021)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

Acute iris depigmentation following systemic moxifloxacin
por: do Nascimento, Heloisa Moraes, et al.
Publicado: (2013)

The role of BRCA1/2 in hereditary and familial breast and ovarian cancers
por: Hawsawi, Yousef M., et al.
Publicado: (2019)

Editorial: BRCA1 and BRCA2 gene mutations screening in sporadic breast cancer patients in Kazakhstan
por: Jankowitz, Rachel C., et al.
Publicado: (2013)

Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers
por: Ananthula, Suryatheja, et al.
Publicado: (2016)

Role of BRCA gene dysfunction in breast and ovarian cancer predisposition
por: Scully, Ralph
Publicado: (2000)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

Looking for BRCA1 and BRCA2 mutations in Asian women with breast cancer
por: Narod, Steven A.
Publicado: (2023)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

The BRCA Gene in Epithelial Ovarian Cancer
por: Sánchez-Lorenzo, Luisa, et al.
Publicado: (2022)

Characterization of BRCA Deficiency in Ovarian Cancer
por: Barbero, Giovanna, et al.
Publicado: (2023)

UPR-induced ovarian cancer cell fusion: a mechanism favoring drug resistance?
por: Husein, Melisa, et al.
Publicado: (2023)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
por: Kalachand, Roshni D., et al.
Publicado: (2020)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2
por: Samuel, David, et al.
Publicado: (2022)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
por: O’Mahony, Denise G., et al.
Publicado: (2023)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
por: Lin, Z. Ping, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ohscppkuj7rgrqq247rulfpn7u